ULORIC® Linked to Cardiovascular Deaths
According to healthycanadians.gc.ca, a post-market clinical study of the medication ULORIC®(febuxostat)indicates that there is an increased risk of cardiovascular (CV) fatal outcomes in patients with gout who have a history of cardiovascular disease when compared to those who are treated with the drug allopurinol. Healthcare … [Read more...] about ULORIC® Linked to Cardiovascular Deaths
FDA Approves Generic Version of Uloric
UNITED STATES – The U.S. Food and Drug Administration has approved a generic version of Uloric, a medication used to treat gout. News about the approval of generic febuxostat comes after the FDA warned earlier this year about an increased risk of death associated with Uloric. Drug company Alembic Pharmaceuticals has announced that … [Read more...] about FDA Approves Generic Version of Uloric
FDA Requires Black Box Warning to be Added to Uloric
As reported online in a news article from thepharmaletter.com, the U.S. Food and Drug Administration has ordered a Black Box warning to be placed on a popular drug prescribed for gout. The warning is associated with newly surfaced information indicating that the drug Uloric is associated with an increased risk of death. For … [Read more...] about FDA Requires Black Box Warning to be Added to Uloric
Uloric, Takeda’s Gout Drug Associated with Serious Side Effects
Gout Drug Uloric Serious Side Effects. Uloric, which is manufactured by Takeda Pharmaceuticals, received U.S. Food and Drug Administration (FDA) approval in February 2009. At that time, ‘Uloric’ was touted as the first new gout medication in over four decades. Since then, the drug has been routinely tied to significant side … [Read more...] about Uloric, Takeda’s Gout Drug Associated with Serious Side Effects
